<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Med. Res</journal-id><journal-title-group><journal-title>European Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0949-2321</issn><issn pub-type="epub">2047-783X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28683820</article-id><article-id pub-id-type="pmc">5501408</article-id><article-id pub-id-type="publisher-id">265</article-id><article-id pub-id-type="doi">10.1186/s40001-017-0265-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>M&#x000fc;nch</surname><given-names>Stefan</given-names></name><address><email>stefan.muench@mri.tum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Heinrich</surname><given-names>Christine</given-names></name><address><email>info@strahlentherapie-agatharied.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Habermehl</surname><given-names>Daniel</given-names></name><address><email>daniel.habermehl@tum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oechsner</surname><given-names>Markus</given-names></name><address><email>markus.oechsner@mri.tum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Combs</surname><given-names>Stephanie E.</given-names></name><address><email>stephanie.combs@tum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Duma</surname><given-names>Marciana-Nona</given-names></name><address><phone>+49-89-4140-5063</phone><email>Marciana.duma@mri.tum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Radiation Oncology, Klinik f&#x000fc;r RadioOnkologie und Strahlentherapie, Klinikum rechts der Isar/TU M&#x000fc;nchen, Ismaninger Str. 22, 81675 Munich, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0483 2525</institution-id><institution-id institution-id-type="GRID">grid.4567.0</institution-id><institution>Institute of Innovative Radiotherapy (iRT), </institution><institution>Helmholtz Zentrum M&#x000fc;nchen, </institution></institution-wrap>Ingolst&#x000e4;dter Landstra&#x000df;e 1, 85764 Oberschlei&#x000df;heim, Germany </aff><aff id="Aff3"><label>3</label>Practice for Radiotherapy, Norbert-Kerkel-Platz 1, 83734 Hausham, Germany </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>22</volume><elocation-id>24</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">In elderly patients with esophageal cancer (EC), esophagectomy is associated with an increased mortality, and therefore these patients are often treated with definite (chemo)radiation. The purpose of this study was to assess the toxicity and efficiency of definite radio(chemo)therapy in patients &#x0003e;75&#x000a0;years compared with definite radio(chemo)therapy in patients &#x0003c;75&#x000a0;years.</p></sec><sec><title>Methods</title><p id="Par2">32 patients &#x0003e;75&#x000a0;years were treated with definite radio(chemo)therapy for EC. We compared baseline parameters, efficiency and toxicity rates of these patients to 39 patients &#x0003c;75&#x000a0;years.</p></sec><sec><title>Results</title><p id="Par3">Patients &#x0003c;75&#x000a0;years were more likely to receive simultaneous chemotherapy, and had a lower age-adjusted Charlson comorbidity index (ACCI). 25% of elderly patients were treated in palliative intent. There was no significant difference in progression-free survival between patient groups. No significant differences were seen for overall survival (15.7&#x000a0;months vs. 19.9&#x000a0;months; <italic>p</italic>&#x000a0;=&#x000a0;0.102) and progression-free survival (10.5&#x000a0;months vs. 9.2&#x000a0;months, <italic>p</italic>&#x000a0;=&#x000a0;0.470) between older patients treated with curative intent and younger patients. In addition, there were no significant differences for dysphagia and hematological side effects between elderly patients and younger patients.</p></sec><sec><title>Conclusion</title><p id="Par4">Definite (chemo)radiation is a feasible therapy for elderly patients. OS and PFS in elderly patients with a curative treatment approach are comparable to younger patients and it is not associated with higher toxicity rates.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par17">Every year, more than 450,000 new cases of esophageal cancer (EC) are diagnosed, and an increase of 140% is predicted over the next ten years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. With a median age of 67&#x000a0;years at diagnosis and 30% of patients being 75&#x000a0;years or older, EC is a cancer of the elderly. Due to demographic changes, this is sure to become a challenge in the near future [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par18">In recent years, studies demonstrated the advantage of neoadjuvant chemoradiation (nCRT) over surgery alone, and therefore, multimodal therapy was established as the standard treatment for patients suitable for surgery [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par19">However, for elder patients (&#x0003e;70&#x02013;80&#x000a0;years) esophagectomy is associated with an increased mortality and lower overall survival than for younger patients [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, the rate of surgery is significant lower among these patients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Instead of surgery, elder patients are often treated with primary radio(chemo)therapy, but, because they are often excluded from clinical trials, different regimes are used for these patients [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Nonetheless, most of the available studies demonstrate the feasibility of definitive radio(chemo)therapy in elderly patients with acceptable survival rates and treatment-related toxicities [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par20">Whether the therapy regimes from younger patients can be applied to elder patients remains controversial, and data are scarcely available. Takeuchi et al. [<xref ref-type="bibr" rid="CR15">15</xref>] compared primary radio(chemo)therapy in 33 patients older than 71&#x000a0;years with 145 patients younger than 70&#x000a0;years. Therapy consisted of radiotherapy up to 60&#x000a0;Gy and simultaneous chemotherapy with 5-fluorouracil and Cisplatin. An age of &#x0003e;71&#x000a0;years was associated with a higher rate of toxicities and an inferior overall survival. After a median follow-up of 57&#x000a0;months, median survival time was 14.7&#x000a0;months for patients &#x0003e;71&#x000a0;years and 35.1&#x000a0;months for patients &#x0003c;70&#x000a0;years. For elderly patients, there was also an increased risk of &#x02265;III&#x000b0; leukopenia or anemia.</p><p id="Par21">The aim of our study was to compare the efficiencies and side effects in patients older than 75&#x000a0;years with the outcomes of younger patients treated with definitive radio(chemo)therapy for esophageal cancer.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par22">Between 1999 and 2014, 32 elderly patients (&#x0003e;75&#x000a0;years) were treated with definite radio(chemo)therapy for EC at our institution. For the control group, we also analyzed 39 younger patients who received definite (chemo)radiation between 2008 and 2014. Efficiency and toxicity was then retrospectively compared between both patient groups. Inclusion criteria were a histologically proven EC and definitive or palliative radio(chemo)therapy without further surgery.</p><p id="Par23">Medical records and follow-up data were used to analyze survival and outcomes of patients. Follow-up of all patients was done according to our institutional guidelines beginning 6&#x02013;8&#x000a0;weeks after treatment and every 3&#x000a0;months thereafter for 2&#x000a0;years and then every 6&#x000a0;months for another 2&#x000a0;years. Follow-up examinations always consisted of a clinical examination and an esophago-gastro-duodenoscopy, and, case by case, of a thoracic computer tomography. In case of missing information, the database of the Munich cancer registry was checked for information about survival or recurrence.</p><p id="Par24">Comorbidities of patients were analyzed based on the &#x0201c;<italic>age</italic>-<italic>adjusted Charlson comorbidity index</italic>&#x0201d; (ACCI) [<xref ref-type="bibr" rid="CR19">19</xref>], which can be used. e.g., as a predictor of early postoperative complications after esophagectomy [<xref ref-type="bibr" rid="CR20">20</xref>]. The performance status was defined according to the Eastern Cooperative Oncology Group (ECOG) definition. Hematological side effects and dysphagia were retrospectively classified according to the common terminology criteria for adverse events (CTCAE) v4.03 after the review of medical records.</p><p id="Par25">Staging by computer tomography was more often available for younger patients than for elderly patients (100% vs. 88%; <italic>p</italic>&#x000a0;=&#x000a0;0.037). While 95% of younger patients were also staged with positron-emission tomography (PET), this was only available for 50% of elderly patients (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The significant difference in PET&#x02013;CT staging is due to the recruitment period of elderly patients. PET/CT staging had not been established as a standard when several of these patients were treated.</p><p id="Par26">For treatment planning, the GTV (primary tumor and lymph node metastases) were delineated using all available diagnostic information (esophago-gastro-duodenoscopy, endosonographic ultrasound, and PET). While the primary tumor and locoregional lymph node metastases were irradiated in all patients, the elective lymphatic pathways were irradiated in all curative treated patients.</p><p id="Par27">Radiotherapy was done by means of 3D-conformal radiotherapy, intensity-modulated radiation therapy (IMRT), or volumetric-modulated arc-therapy (VMAT). As different radiotherapy fractionations were used for the older patients (1.8&#x02013;3&#x000a0;Gy single doses to total doses of 7&#x02013;65&#x000a0;Gy) in this study, we report the cumulative 2&#x000a0;Gy equivalent dose (EQD2). The EQD2 was calculated with an &#x003b1;/&#x003b2; ratio of 10.</p><p id="Par28">The distribution of quantitative data is described by median and interquartile range (IQR). Likewise, qualitative data are presented as absolute and relative frequencies. Corresponding statistical hypothesis analyses are performed using Wilcoxon&#x02013;Mann&#x02013;Whitney-U tests and Fisher&#x02019;s exact test, respectively. Overall survival (OS) and progression-free-survival (PFS) where calculated from results at the end of the therapy. The comparison between patient groups was done by the log-rank-tests. All statistical analyses were conducted in an exploratory manner on two-sided 5% significance levels using the software <italic>PASW Statistics 18 version 18.0.0.</italic>
</p></sec><sec id="Sec3"><title>Results</title><p id="Par29">The median age of the elderly patients&#x02019; was 82&#x000a0;years (IQR 79&#x02013;84&#x000a0;years), whereas the median age of the younger patients&#x02019; was 66&#x000a0;years (IQR 59&#x02013;72&#x000a0;years; <italic>p</italic>&#x000a0;=&#x000a0;1.000). The ECOG status of patients &#x0003e;75&#x000a0;years was lower than that of the younger patients. 20% of elderly patients had an ECOG status of &#x0201c;0.&#x0201d; 73% had a status of &#x0201c;1.&#x0201d; and 7% had a status of &#x0201c;2,&#x0201d; whereas almost 73% of patients &#x0003c;75&#x000a0;years had an ECOG performance status of &#x0201c;0,&#x0201d; and 27% had a status of &#x0201c;1&#x0201d; (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Elderly patients also had more comorbidities with a higher median ACCI than had the younger patients (7 vs. 3; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0,001). All (100%) of the younger patients had a squamous cell carcinoma (SCC) of the esophagus. In contrast to this, 19% of elderly patients were diagnosed with adenocarcinoma and 81% with SCC. While no significant differences between the patient groups were observed for the other baseline characteristics such as sex, TNM classification, UICC-stage, grading, tumor length, and localization, significantly more elderly patients were treated in palliative intent (25% vs. 0%; <italic>p</italic>&#x000a0;=&#x000a0;0.001) and also were less likely to receive any kind of chemotherapy (40.6% vs. 82.1%; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Compared with elderly patients with curative intent, younger patients were more likely to have adenocarcinoma (21% vs. 0%; <italic>p</italic>&#x000a0;=&#x000a0;0.006), had a higher ACCI (7 vs. 4; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), and had a higher ECOG performance status (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In addition, younger patients were also more likely to receive simultaneous chemotherapy (82% vs. 42%; <italic>p</italic>&#x000a0;=&#x000a0;0.002) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patients&#x02019; characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Patient characteristics</th><th align="left" colspan="2">Age &#x0003e;75&#x000a0;years only curative intent (<italic>n</italic>&#x000a0;=&#x000a0;24)</th><th align="left" colspan="2">Age &#x0003e;75&#x000a0;years only palliative intent (<italic>n</italic>&#x000a0;=&#x000a0;8)</th><th align="left" colspan="2">Age &#x02264;75&#x000a0;years<break/>(<italic>n</italic>&#x000a0;=&#x000a0;39)</th><th align="left">
<italic>p</italic> value<sup>a</sup>
</th></tr><tr><th align="left" rowspan="2">%</th><th align="left">Median</th><th align="left">%</th><th align="left">Median</th><th align="left">%</th><th align="left">Median</th><th align="left" rowspan="2"/></tr><tr><th align="left">(IQR 25&#x02013;75)</th><th align="left"/><th align="left">(IQR 25&#x02013;75)</th><th align="left"/><th align="left">(IQR 25&#x02013;75)</th></tr></thead><tbody><tr><td align="left" colspan="7">Sex</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;Male (%)</td><td align="left">66.7</td><td align="left"/><td align="left">62.5</td><td align="left"/><td align="left">66.7</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">Age in years</td><td align="left" rowspan="2"/><td align="left">81</td><td align="left"/><td align="left">83</td><td align="left"/><td align="left">66</td><td char="." align="char" rowspan="2">&#x0003c;0.001</td></tr><tr><td align="left">(78&#x02013;85)</td><td align="left"/><td align="left">(79&#x02013;84)</td><td align="left"/><td align="left">(59&#x02013;72)</td></tr><tr><td align="left" colspan="7">ECOG</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">&#x000a0;0</td><td align="left">17.4</td><td align="left"/><td align="left">28.6</td><td align="left"/><td align="left">73.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;1</td><td align="left">78.3</td><td align="left"/><td align="left">57.1</td><td align="left"/><td align="left">27.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;2</td><td align="left">4.3</td><td align="left"/><td align="left">14.3</td><td align="left"/><td align="left">0.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">ACCI</td><td align="left" rowspan="2"/><td align="left">7</td><td align="left"/><td align="left">8</td><td align="left"/><td align="left">4</td><td char="." align="char" rowspan="2">&#x0003c;0.001</td></tr><tr><td align="left">(6&#x02013;8)</td><td align="left"/><td align="left">(6&#x02013;9)</td><td align="left"/><td align="left">(4&#x02013;5)</td></tr><tr><td align="left" colspan="7">Histology</td><td char="." align="char">0.006</td></tr><tr><td align="left">&#x000a0;SCC (%)</td><td align="left">79.2</td><td align="left"/><td align="left">66.7</td><td align="left"/><td align="left">100.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Adenocarcinoma (%)</td><td align="left">20.8</td><td align="left"/><td align="left">33.3</td><td align="left"/><td align="left">0.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">Primary tumor extension</td><td char="." align="char">0.353</td></tr><tr><td align="left">&#x000a0;cT1 (%)</td><td align="left">12.5</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">8.1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;cT2 (%)</td><td align="left">4.2</td><td align="left"/><td align="left">37.5</td><td align="left"/><td align="left">5.4</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;cT3 (%)</td><td align="left">83.3</td><td align="left"/><td align="left">62.5</td><td align="left"/><td align="left">75.7</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;cT4 (%)</td><td align="left">0</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">10.8</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">Lymph node extension</td><td char="." align="char">0.721</td></tr><tr><td align="left">&#x000a0;cN+ (%)</td><td align="left">83.3</td><td align="left"/><td align="left">100</td><td align="left"/><td align="left">87.2</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">Distant metastasis</td><td char="." align="char">0.268</td></tr><tr><td align="left">&#x000a0;M1 (%)</td><td align="left">0</td><td align="left"/><td align="left">25</td><td align="left"/><td align="left">8.3</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">UICC-stage</td><td char="." align="char">0.239</td></tr><tr><td align="left">&#x000a0;IA (%)</td><td align="left">8.3</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;IIA (%)</td><td align="left">8.3</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">11.1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;IIB (%)</td><td align="left">8.3</td><td align="left"/><td align="left">37.5</td><td align="left"/><td align="left">11.1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;IIIA (%)</td><td align="left">75</td><td align="left"/><td align="left">50</td><td align="left"/><td align="left">61,1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;IIIC (%)</td><td align="left">0</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">8.3</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td align="left">0</td><td align="left"/><td align="left">12.5</td><td align="left"/><td align="left">8.3</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">Grading</td><td char="." align="char">0.492</td></tr><tr><td align="left">&#x000a0;G1 (%)</td><td align="left">4.2</td><td align="left"/><td align="left">0</td><td align="left"/><td align="left">0.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;G2 (%)</td><td align="left">50</td><td align="left"/><td align="left">25</td><td align="left"/><td align="left">57.1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;G3 (%)</td><td align="left">45.8</td><td align="left"/><td align="left">75</td><td align="left"/><td align="left">42.9</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="7">Tumor localization</td><td char="." align="char">0.195</td></tr><tr><td align="left">&#x000a0;Upper third (%)</td><td align="left">26.1</td><td align="left"/><td align="left">25</td><td align="left"/><td align="left">42.1</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Middle third (%)</td><td align="left">43.5</td><td align="left"/><td align="left">50</td><td align="left"/><td align="left">23.7</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Lower third (%)</td><td align="left">30.4</td><td align="left"/><td align="left">25</td><td align="left"/><td align="left">34.2</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">Tumor length (centimeter)</td><td align="left" rowspan="2"/><td align="left">5</td><td align="left"/><td align="left">7</td><td align="left"/><td align="left">5</td><td char="." align="char" rowspan="2">0.245</td></tr><tr><td align="left">(3&#x02013;7)</td><td align="left"/><td align="left">(5&#x02013;9)</td><td align="left"/><td align="left">(5&#x02013;7)</td></tr><tr><td align="left">Discontinuation of treatment (%)</td><td align="left">0.0</td><td align="left"/><td align="left">60</td><td align="left"/><td align="left">0.0</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Simultaneous chemotherapy (%)</td><td align="left">41.7</td><td align="left"/><td align="left">37.5</td><td align="left"/><td align="left">82.1</td><td align="left"/><td char="." align="char">0.002</td></tr><tr><td align="left" rowspan="2">EQD2 (Gy)</td><td align="left" rowspan="2"/><td align="left">54</td><td align="left"/><td align="left">40</td><td align="left"/><td align="left">53</td><td char="." align="char" rowspan="2">0.417</td></tr><tr><td align="left">(53&#x02013;55)</td><td align="left"/><td align="left">(19&#x02013;46)</td><td align="left"/><td align="left">(53&#x02013;54)</td></tr><tr><td align="left" rowspan="2">Overall dose (Gy)</td><td align="left" rowspan="2"/><td align="left">54</td><td align="left"/><td align="left">38</td><td align="left"/><td align="left">54</td><td char="." align="char" rowspan="2">0.860</td></tr><tr><td align="left">(54&#x02013;56)</td><td align="left"/><td align="left">(20&#x02013;45)</td><td align="left"/><td align="left">(54&#x02013;54)</td></tr><tr><td align="left" rowspan="2">Daily dose (Gy)</td><td align="left" rowspan="2"/><td align="left">1.8</td><td align="left"/><td align="left">2.0</td><td align="left"/><td align="left">1.8</td><td char="." align="char" rowspan="2">0.127</td></tr><tr><td align="left">(1.8&#x02013;2)</td><td align="left"/><td align="left">(1.8&#x02013;2.5)</td><td align="left"/><td align="left">(1.8&#x02013;1.8)</td></tr></tbody></table><table-wrap-foot><p>The most common side effect was dysphagia. All of the elderly patients and more than 84% of the younger patients described some kind of dysphagia. No significant differences were seen for acute hematological toxicities and dysphagia when comparing younger patients with all elderly patients, as seen in the case when younger patients are compared with elderly patients with only curative intent (Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>)</p><p>
<italic>SCC</italic> squamous cell carcinoma, <italic>EQD2</italic> 2&#x000a0;Gy equivalent dose, <italic>ECOG</italic> Eastern Cooperative Oncology Group performance status, <italic>ACCI</italic> age-adjusted Charlson comorbidity Index</p><p>
<sup>a</sup>
<italic>p</italic> value refers to the comparison between younger patients and elderly patients with curative intent</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Adverse events for all patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Adverse events</th><th align="left">Age &#x0003e;75&#x000a0;years<break/>(<italic>n</italic>&#x000a0;=&#x000a0;32)</th><th align="left">Age &#x02264;75&#x000a0;years<break/>(<italic>n</italic>&#x000a0;=&#x000a0;39)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="3">Dyspahgia (CTCAE)</td><td char="." align="char">0.132</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">0.0</td><td char="." align="char">15.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">50.0</td><td char="." align="char">43.6</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">28.1</td><td char="." align="char">20.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">21.9</td><td char="." align="char">17.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">0.0</td><td char="." align="char">2.6</td><td align="left"/></tr><tr><td align="left" colspan="3">Leukopenia (CTCAE)</td><td char="." align="char">0.105</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">34.4</td><td char="." align="char">26.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">18.7</td><td char="." align="char">18.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">37.5</td><td char="." align="char">26.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">6.3</td><td char="." align="char">29.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">3.1</td><td char="." align="char">0.0</td><td align="left"/></tr><tr><td align="left" colspan="3">Anemia (CTCAE)</td><td char="." align="char">0.157</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">3.1</td><td char="." align="char">17.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">56.3</td><td char="." align="char">38.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">37.5</td><td char="." align="char">41.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">3.1</td><td char="." align="char">2.6</td><td align="left"/></tr><tr><td align="left" colspan="3">Thrombocytopenia (CTCAE)</td><td char="." align="char">0.795</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">31.3</td><td char="." align="char">34.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">50.0</td><td char="." align="char">51.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">18.7</td><td char="." align="char">11.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">0.0</td><td char="." align="char">0.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">0.0</td><td char="." align="char">2.9</td><td align="left"/></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Adverse events for patients with curative intent only</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Adverse events</th><th align="left">Age &#x0003e;75&#x000a0;years<break/>(<italic>n</italic>&#x000a0;=&#x000a0;24)</th><th align="left">Age &#x02264;75&#x000a0;years<break/>(<italic>n</italic>&#x000a0;=&#x000a0;39)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="3">Dyspahgia (CTCAE)</td><td char="." align="char">0.187</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">0.0</td><td char="." align="char">15.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">54.2</td><td char="." align="char">43.6</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">33.3</td><td char="." align="char">20.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">12.5</td><td char="." align="char">17.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">0.0</td><td char="." align="char">2.6</td><td align="left"/></tr><tr><td align="left" colspan="3">Leukopenia (CTCAE)</td><td char="." align="char">0.157</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">33.3</td><td char="." align="char">26.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">12.5</td><td char="." align="char">18.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">41.7</td><td char="." align="char">26.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">8.3</td><td char="." align="char">29.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">4.2</td><td char="." align="char">0.0</td><td align="left"/></tr><tr><td align="left" colspan="3">Anemia (CTCAE)</td><td char="." align="char">0.061</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">0.0</td><td char="." align="char">17.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">62.5</td><td char="." align="char">38.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">33.3</td><td char="." align="char">41.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">4.2</td><td char="." align="char">2.6</td><td align="left"/></tr><tr><td align="left" colspan="3">Thrombocytopenia (CTCAE)</td><td char="." align="char">0.958</td></tr><tr><td align="left">&#x000a0;0&#x000b0; (%)</td><td char="." align="char">29.2</td><td char="." align="char">34.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x000b0; (%)</td><td char="." align="char">58.3</td><td char="." align="char">51.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;II&#x000b0; (%)</td><td char="." align="char">12.5</td><td char="." align="char">11.4</td><td align="left"/></tr><tr><td align="left">&#x000a0;III&#x000b0; (%)</td><td char="." align="char">0.0</td><td char="." align="char">0.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;IV (%)</td><td char="." align="char">0.0</td><td char="." align="char">2.9</td><td align="left"/></tr></tbody></table></table-wrap>
</p><p id="Par30">Of the 31 younger patients who received simultaneous chemotherapy, 29 (94%) received a combination of cisplatinum (20&#x000a0;mg/m<sup>2</sup>/day; days 1&#x02013;5 and days 29&#x02013;33) and 5-fluorouracil (500&#x000a0;mg/m<sup>2</sup>/day; days 1&#x02013;5 and days 29&#x02013;33). In two other younger patients (6%), simultaneous chemotherapy was performed with 5-fluorouracil only (250&#x000a0;mg/m<sup>2</sup>/day, continuous).</p><p id="Par31">Of the 13 older patients who received simultaneous chemotherapy, eight patients (62%) received a combination of cisplatinum (20&#x000a0;mg/m<sup>2</sup>/day; days 1&#x02013;5 and days 29&#x02013;33) and 5-fluorouracil (500&#x000a0;mg/m<sup>2</sup>/day;, days 1&#x02013;5 and days 29&#x02013;33). Simultaneous chemotherapy with 5-fluorouracil (250&#x000a0;mg/m<sup>2</sup>/day; continuous) only or cisplatinum (40&#x000a0;mg/m<sup>2</sup>/day; weekly) only was performed in two patients and two patients, respectively. In one another patient, chemotherapy was performed with carboplatinum (area under the curve 5, week 1&#x000a0;+&#x000a0;5).</p><p id="Par32">One of the younger patients and one elderly patient each received additional induction chemotherapy with 2 cycles of cisplatinum and 5-fluorouracil.</p><p id="Par33">On comparing the side effects between younger patients and older patients who received simultaneous chemoradiation (<italic>n</italic>&#x000a0;=&#x000a0;10), there was no significant differences for dysphagia, anemia, and thrombocytopenia. In contrast, I&#x000b0;&#x02013;IV&#x000b0; leukopenia was seen in 0, 70, 10, and 10% of older patients and 19, 29, 35, and 0% of younger patients, respectively (<italic>p</italic>&#x000a0;=&#x000a0;0.037).</p><sec id="Sec4"><title>Local control</title><p id="Par34">48.6% of younger patients and 41.6% of older patients with curative intent had a local relapse. However, this difference was not statistically significant (<italic>p</italic>&#x000a0;=&#x000a0;0.611).</p></sec><sec id="Sec5"><title>Survival</title><p id="Par35">Median follow-up was 15.4 (IQR 5.3&#x02013;23.2)&#x000a0;months for elderly patients with curative intent and 18.3 (IQR 6.8&#x02013;38.2)&#x000a0;months for corresponding younger patients.</p><p id="Par36">Median overall survival (OS) was 7.7&#x000a0;months for elderly patients and 19.9&#x000a0;months for younger patients (<italic>p</italic>&#x000a0;=&#x000a0;0.016). However, there was no significant difference for OS in younger patients compared with elderly patients with a curative treatment intent (15.7&#x000a0;months vs. 19.9&#x000a0;months; <italic>p</italic>&#x000a0;=&#x000a0;0.102) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Elderly patients treated with a palliative treatment intent had a median OS of 2.7&#x000a0;months.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Overall survival of patients treated with a curative treatment approach</p></caption><graphic xlink:href="40001_2017_265_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par37">No significant differences in PFS were seen between younger patients and all older patients (9.2&#x000a0;months vs. 7.6&#x000a0;months; <italic>p</italic>&#x000a0;=&#x000a0;0.203), or when comparing younger patients with older patients treated with curative intent (9.2&#x000a0;months vs. 10.5&#x000a0;months; <italic>p</italic>&#x000a0;=&#x000a0;0.470) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Progression-free survival of patients treated with a curative treatment approach</p></caption><graphic xlink:href="40001_2017_265_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec6"><title>Discussion</title><p id="Par38">In this study, we evaluated the toxicities and the outcome of definite radio(chemo)therapy for esophageal cancer in patients older than 75&#x000a0;years compared with patients younger than 75&#x000a0;years. Our study has some limitations. The most important is it is retrospective in nature with all the inherent problems concerning follow-up data. One way that we tried to compensate for the missing of follow-up data was the use of the Munich cancer registry survival data.</p><p id="Par39">Despite these limitations, our results are comparable to those available in the literature. Two studies by Minsky et al. [<xref ref-type="bibr" rid="CR21">21</xref>] and Conroy et al. [<xref ref-type="bibr" rid="CR22">22</xref>] investigated the efficiencies of (curative) radio(chemo)therapy in patients with esophageal cancer. In 109 patients with a median age of 64&#x000a0;years, who were treated with 50.4&#x000a0;Gy and a concurrent chemotherapy with cisplatinum and 5-fluorouracil median overall survival was 18.1&#x000a0;months [<xref ref-type="bibr" rid="CR21">21</xref>]. Another group of 133 patients with a mean age of 60&#x000a0;years, treated with 50&#x000a0;Gy and concurrent chemotherapy with cisplatinum and 5-fluorouracil, had a median overall survival of 17.5&#x000a0;months and a progression-free survival of 9.4&#x000a0;months [<xref ref-type="bibr" rid="CR22">22</xref>]. The results are similar to those of our younger patient group.</p><p id="Par40">When excluding patients with palliative treatment intent, OS and PFS of elderly patients in our study were 15.7&#x000a0;months and 9.2&#x000a0;months, respectively. These results correspond very well to the results mentioned above and indicate that radio(chemo)therapy is as effective in patients &#x0003e;75&#x000a0;years as in younger patients.</p><p id="Par41">Previous studies about curative radio(chemo)therapy demonstrated the feasibility of this in elderly patients [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In a study by Rochigneux et al. [<xref ref-type="bibr" rid="CR18">18</xref>], 58 patients with a median age of 77.9&#x000a0;years were treated with definite radio(chemo)therapy and a mean radiation dose of 50.9&#x000a0;Gy. OS and PFS were 14.5 and 9.6&#x000a0;months, respectively. When we compare only the elderly patients treated in our institution in a curative intent, there was just a small difference in OS (15.7 vs. 14.5&#x000a0;months) and PFS (11.8 vs. 9.2&#x000a0;months) relative to the Rochigneux et al. study. In another study by Tougeron et al. [<xref ref-type="bibr" rid="CR14">14</xref>], 109 patients older than 70&#x000a0;years with a mean age of 74.4&#x000a0;years were treated with definite radio(chemo)therapy for EC. Median OS and PFS were 15.3 and 8.2&#x000a0;months, respectively.</p><p id="Par42">One fairly recent prospective study analyzed the efficacy and toxicity of palliative chemoradiotherapy in 25 patients with advanced/metastatic esophageal cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. The palliation aim was the reduction of dysphagia. All patients were younger than 75&#x000a0;years and received concomitant chemoradiation. The overall survival in this study was 7&#x000a0;months. Our study had an OS of approximately 3&#x000a0;months in the palliative treatment group of elderly patients. However, it is to be noted that many of our elderly patients had more comorbidities, a higher ACCI score, and a lower ECOG-score than the younger patients in our group. It could be hypothesized that the younger age&#x02014;probably paired with a better ACCI and ECOG scores&#x02014;and the combination with systemic treatment in the Akl et al. study explains the difference in OS.</p><p id="Par43">No significant differences of toxicities were found between younger patients and elder patients, neither for the whole group nor for the elder patients treated in curative intent.</p><p id="Par44">Compared to the results by Rochigneux et al. [<xref ref-type="bibr" rid="CR18">18</xref>], there is a similar rate of grade 3&#x02013;4 dysphagia in elderly patients (21.9% vs. 19.1%).</p><p id="Par45">Younger patients were more often staged with CT and or PET/CT than elderly patients, which might cause a bias. However, in absolute numbers, CT staging was only missing in three elderly patients treated with curative intent and one elderly patient with palliative intent. There was much larger difference regarding the availability of PET between older patients and younger patients (95% vs. 50%).The significant difference in PET&#x02013;CT staging is due to the recruitment period of elderly patients. PET/CT staging was not established as a standard when several of these patients were treated. However, as PET&#x02013;CT might point out the metastatic patients, who will not undergo primary radiochemotherapy, the lack thereof might only make the results worse in the elderly group.</p></sec><sec id="Sec7"><title>Conclusion</title><p id="Par46">Definitive radio(chemo)therapy for esophageal cancer is a feasibly therapy for elderly (in our study with a median age of 82&#x000a0;years) patients. Despite the fact that elderly patients have more comorbidities, a lower ECOG-score and receive less chemotherapy, there are just negligible differences in OS and PFS when stratifying for treatment approach. In elderly patients with a curative treatment approach, results are comparable with younger patients, without an increased risk for radiotherapy induced dysphagia or hematological side effects.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>EC</term><def><p id="Par5">esophageal cancer</p></def></def-item><def-item><term>ACCI</term><def><p id="Par6">adjusted Charlson comorbidity index</p></def></def-item><def-item><term>nCRT</term><def><p id="Par7">neoadjuvant chemoradiation</p></def></def-item><def-item><term>ECOG</term><def><p id="Par8">Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>CTCAE</term><def><p id="Par9">common terminology criteria for adverse events</p></def></def-item><def-item><term>IMRT</term><def><p id="Par10">intensity-modulated radiation therapy</p></def></def-item><def-item><term>VMAT</term><def><p id="Par11">volumetric-modulated arc-therapy</p></def></def-item><def-item><term>EQD2</term><def><p id="Par12">2&#x000a0;Gy equivalent dose</p></def></def-item><def-item><term>IQR</term><def><p id="Par13">interquartile range</p></def></def-item><def-item><term>OS</term><def><p id="Par14">overall survival</p></def></def-item><def-item><term>PFS</term><def><p id="Par15">progression-free survival</p></def></def-item><def-item><term>SCC</term><def><p id="Par16">squamous cell carcinoma</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>SM: responsible for the acquisition of data, analysis, and interpretation of data, and for drafting of the manuscript. CH: for the acquisition of data, and for the analysis and Interpretation of data. DH: for the analysis and interpretation of data, and for the critical revision. MO: for the analysis and interpretation of data. SC: for the critical revision. MND: for the study conception and design, and for the critical revision.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par47">None.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par48">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par49">The datasets used during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par50">All authors gave consent to publication. No individual patient data are reported.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par51">The study was approved by the ethics committee of the Technische Universit&#x000e4;t M&#x000fc;nchen (34/16 S). Due to the retrospective nature of this study there is no specific consent to participate.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par52">This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par53">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>A</given-names></name><etal/></person-group><article-title>Oesophageal carcinoma</article-title><source>Lancet</source><year>2013</year><volume>381</volume><issue>9864</issue><fpage>400</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60643-6</pub-id><pub-id pub-id-type="pmid">23374478</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napier</surname><given-names>KJ</given-names></name><name><surname>Scheerer</surname><given-names>M</given-names></name><name><surname>Misra</surname><given-names>S</given-names></name></person-group><article-title>Esophageal cancer: a Review of epidemiology, pathogenesis, staging workup and treatment modalities</article-title><source>World J Gastrointest Oncol</source><year>2014</year><volume>6</volume><issue>5</issue><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.4251/wjgo.v6.i5.112</pub-id><pub-id pub-id-type="pmid">24834141</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975&#x02013;2012, National Cancer Institute. Bethesda, MD, <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2012/">http://seer.cancer.gov/csr/1975_2012/</ext-link>, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjoquist</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><issue>7</issue><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70142-5</pub-id><pub-id pub-id-type="pmid">21684205</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>1090</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00040-6</pub-id><pub-id pub-id-type="pmid">26254683</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kranzfelder</surname><given-names>M</given-names></name><etal/></person-group><article-title>Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer</article-title><source>Br J Surg</source><year>2011</year><volume>98</volume><issue>6</issue><fpage>768</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1002/bjs.7455</pub-id><pub-id pub-id-type="pmid">21462364</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markar</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy</article-title><source>Dis Esophagus</source><year>2013</year><volume>26</volume><issue>3</issue><fpage>250</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2050.2012.01353.x</pub-id><pub-id pub-id-type="pmid">22591068</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HX</given-names></name><etal/></person-group><article-title>Outcome of elderly patients with oesophageal squamous cell carcinoma after surgery</article-title><source>Br J Surg</source><year>2010</year><volume>97</volume><issue>6</issue><fpage>862</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1002/bjs.7005</pub-id><pub-id pub-id-type="pmid">20301165</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cijs</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Outcome of esophagectomy for cancer in elderly patients</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>90</volume><issue>3</issue><fpage>900</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2010.05.039</pub-id><pub-id pub-id-type="pmid">20732515</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskovitz</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>82</volume><issue>6</issue><fpage>2031</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2006.06.053</pub-id><pub-id pub-id-type="pmid">17126106</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin-Fenton</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><issue>3</issue><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.10.011</pub-id><pub-id pub-id-type="pmid">17140789</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steyerberg</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>17</issue><fpage>2389</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.7931</pub-id><pub-id pub-id-type="pmid">17557952</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Combined modality chemoradiation in elderly oesophageal cancer patients</article-title><source>Br J Cancer</source><year>2007</year><volume>96</volume><issue>12</issue><fpage>1823</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603821</pub-id><pub-id pub-id-type="pmid">17533399</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tougeron</surname><given-names>D</given-names></name><etal/></person-group><article-title>Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><issue>10</issue><fpage>1586</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604749</pub-id><pub-id pub-id-type="pmid">19002180</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer</article-title><source>Am J Clin Oncol</source><year>2007</year><volume>30</volume><issue>6</issue><fpage>607</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1097/COC.0b013e3180ca7c84</pub-id><pub-id pub-id-type="pmid">18091055</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>T</given-names></name><etal/></person-group><article-title>Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer</article-title><source>Onco Targets Ther</source><year>2015</year><volume>8</volume><fpage>3087</fpage><lpage>3094</lpage><pub-id pub-id-type="pmid">26543377</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Servagi-Vernat</surname><given-names>S</given-names></name><etal/></person-group><article-title>Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged&#x000a0;&#x0003e;&#x000a0;or&#x000a0;=&#x000a0;75&#x000a0;years: a prospective, single-arm phase II study</article-title><source>Drugs Aging</source><year>2009</year><volume>26</volume><issue>3</issue><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.2165/00002512-200926030-00006</pub-id><pub-id pub-id-type="pmid">19358620</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochigneux</surname><given-names>P</given-names></name><etal/></person-group><article-title>Radio(chemo)therapy in elderly patients with esophageal cancer: a feasible treatment with an outcome consistent with younger patients</article-title><source>Front Oncol</source><year>2014</year><volume>4</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.3389/fonc.2014.00100</pub-id><pub-id pub-id-type="pmid">24860783</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Validation of a combined comorbidity index</article-title><source>J Clin Epidemiol</source><year>1994</year><volume>47</volume><issue>11</issue><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(94)90129-5</pub-id><pub-id pub-id-type="pmid">7722560</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname><given-names>B</given-names></name><etal/></person-group><article-title>Assessment of different prognostic scores for early postoperative outcomes after esophagectomy</article-title><source>Chirurgia (Bucur)</source><year>2014</year><volume>109</volume><issue>4</issue><fpage>480</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">25149610</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minsky</surname><given-names>BD</given-names></name><etal/></person-group><article-title>INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><issue>5</issue><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.20.5.1167</pub-id><pub-id pub-id-type="pmid">11870157</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>T</given-names></name><etal/></person-group><article-title>Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70028-2</pub-id><pub-id pub-id-type="pmid">24556041</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>FM</given-names></name><name><surname>Elsayed-Abd-Alkhalek</surname><given-names>S</given-names></name><name><surname>Salah</surname><given-names>T</given-names></name></person-group><article-title>Palliative concurrent chemoradiotherapy in locally advanced and metastatic esophageal cancer patients with dysphagia</article-title><source>Ann Palliat Med</source><year>2013</year><volume>2</volume><issue>3</issue><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">25842093</pub-id></element-citation></ref></ref-list></back></article>